ATLANTA, GA – – (Newsfile Corp. – July 6, 2021) – – Holzer & Holzer, LLC is investigating whether Provention Bio, Inc. (“Provention” or the “Company”) (NASDAQ: PRVB) complied with federal securities laws.  On July 6, 2021, Provention announced the issuance of a Complete Response Letter (“CRL”) by the FDA for the Company’s Biologics License Application (“BLA”) for the drug Teplizumab. Specifically, the FDA noted that a recent study “failed to show Pharmacokinetic comparability” and notified Provention that it must either demonstrate PK compatibility for Teplizumab or provide other data showing why PK compatibility is not necessary. After the Company’s announcement, the price of Provention significantly dropped. If you purchased shares of Provention stock and suffered a loss on that investment, you are encouraged to either contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

Provide Your Information To Take Action

  • Plaintiff Certifies That:
    1. Plaintiff has reviewed the complaint and authorized its filing.
    2. Plaintiff did not acquire the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this private action or any other litigation under the federal securities laws.
    3. Plaintiff is willing to serve as a representative party on behalf of a class, including providing testimony at deposition and trial, if necessary.
    4. Plaintiff represents and warrants that he/she/it is fully authorized to enter into and execute this certification.
    5. Plaintiff will not accept any payment for serving as a representative party on behalf of a class beyond the Plaintiff's pro rata share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.
    6. Plaintiff has made no transaction(s) during the Class Period in the debt or equity securities that are the subject of this action except those set forth below:
  • Date PurchasedNumber of Shares AcquiredAcquisition Price Per Share 
  • Date SoldNumber of Shares SoldSelling Price Per Share 
  • Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt